These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26484876)

  • 21. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
    Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
    PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
    Caudal D; Alvarsson A; Björklund A; Svenningsson P
    Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic effects of repetitive transcranial magnetic stimulation in an animal model of Parkinson's disease.
    Lee JY; Kim SH; Ko AR; Lee JS; Yu JH; Seo JH; Cho BP; Cho SR
    Brain Res; 2013 Nov; 1537():290-302. PubMed ID: 23998987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model.
    Sanchez-Guajardo V; Annibali A; Jensen PH; Romero-Ramos M
    J Neuropathol Exp Neurol; 2013 Jul; 72(7):624-45. PubMed ID: 23771222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential role of α-synuclein in neurodegeneration: studies in a rat animal model.
    Stoica G; Lungu G; Bjorklund NL; Taglialatela G; Zhang X; Chiu V; Hill HH; Schenk JO; Murray I
    J Neurochem; 2012 Aug; 122(4):812-22. PubMed ID: 22639889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
    Gaugler MN; Genc O; Bobela W; Mohanna S; Ardah MT; El-Agnaf OM; Cantoni M; Bensadoun JC; Schneggenburger R; Knott GW; Aebischer P; Schneider BL
    Acta Neuropathol; 2012 May; 123(5):653-69. PubMed ID: 22361813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comprehensive study on long-term injury to nigral dopaminergic neurons following intracerebroventricular injection of lipopolysaccharide in rats.
    Zhou Y; Zhang Y; Li J; Lv F; Zhao Y; Duan D; Xu Q
    J Neurochem; 2012 Dec; 123(5):771-80. PubMed ID: 22957701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular models for Parkinson's disease.
    Falkenburger BH; Saridaki T; Dinter E
    J Neurochem; 2016 Oct; 139 Suppl 1():121-130. PubMed ID: 27091001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease.
    Maia S; Arlicot N; Vierron E; Bodard S; Vergote J; Guilloteau D; Chalon S
    Synapse; 2012 Jul; 66(7):573-83. PubMed ID: 22337286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuronal vulnerability in Parkinson's disease.
    Double KL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. α-synuclein promotes neuroprotection through NF-κB-mediated transcriptional regulation of protein kinase Cδ.
    Aoki R; Li YR
    Sci Signal; 2011 Oct; 4(195):jc6. PubMed ID: 22009151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease.
    Kim M; Cho KH; Shin MS; Lee JM; Cho HS; Kim CJ; Shin DH; Yang HJ
    Int J Mol Med; 2014 Apr; 33(4):870-8. PubMed ID: 24535622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of repetitive transcranial magnetic stimulation on a model rat of Parkinson's disease.
    Yang X; Song L; Liu Z
    Neuroreport; 2010 Mar; 21(4):268-72. PubMed ID: 20087233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra.
    Klein RL; King MA; Hamby ME; Meyer EM
    Hum Gene Ther; 2002 Mar; 13(5):605-12. PubMed ID: 11916484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
    Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
    Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
    Yamada M; Mizuno Y; Mochizuki H
    Hum Gene Ther; 2005 Feb; 16(2):262-70. PubMed ID: 15761265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.
    Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH
    PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra.
    Pino E; Amamoto R; Zheng L; Cacquevel M; Sarria JC; Knott GW; Schneider BL
    Hum Mol Genet; 2014 Mar; 23(6):1435-52. PubMed ID: 24158851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity.
    Batelli S; Invernizzi RW; Negro A; Calcagno E; Rodilossi S; Forloni G; Albani D
    Neurodegener Dis; 2015; 15(1):13-23. PubMed ID: 25500798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.